Stockscreener 앱 받기
69.53
0.51%
0.35
시간 외 거래:
69.54
0.01
+0.01%
전일 마감가:
$69.18
열려 있는:
$69.13
하루 거래량:
1.05M
Relative Volume:
1.98
시가총액:
$2.67B
수익:
-
순이익/손실:
$-241.60M
주가수익비율:
-10.51
EPS:
-6.6167
순현금흐름:
$-201.34M
1주 성능:
-0.76%
1개월 성능:
-13.30%
6개월 성능:
+17.58%
1년 성능:
+11.02%
1일 변동 폭
$67.70
$69.60
1주일 범위
$66.72
$72.07
52주 변동 폭
$40.00
$99.50
Disc Medicine Inc Stock (IRON) Company Profile
명칭
Disc Medicine Inc
전화
(617) 674-9274
주소
321 ARSENAL STREET, SUITE 101, WATERTOWN
Compare IRON vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IRON
Disc Medicine Inc
|
69.53 | 2.69B | 0 | -241.60M | -201.34M | -6.6167 |
VRTX
Vertex Pharmaceuticals Inc
|
508.34 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
784.85 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
990.32 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
154.04 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
190.95 | 43.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Disc Medicine Inc Stock (IRON) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-03 | 재개 | Stifel | Buy |
| 2025-07-21 | 개시 | Truist | Buy |
| 2025-07-03 | 재개 | Morgan Stanley | Overweight |
| 2025-06-11 | 재개 | Raymond James | Strong Buy |
| 2025-02-27 | 개시 | TD Cowen | Buy |
| 2024-11-05 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-11-04 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2024-10-23 | 개시 | Jefferies | Buy |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-08-22 | 개시 | Wells Fargo | Overweight |
| 2024-04-01 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2023-12-19 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-06-09 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2023-06-07 | 개시 | H.C. Wainwright | Buy |
| 2023-05-17 | 개시 | Raymond James | Outperform |
| 2023-04-28 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-04-21 | 개시 | Stifel | Buy |
| 2023-04-20 | 개시 | Morgan Stanley | Overweight |
| 2023-03-23 | 개시 | BMO Capital Markets | Outperform |
| 2023-02-28 | 개시 | SVB Securities | Outperform |
모두보기
Disc Medicine Inc 주식(IRON)의 최신 뉴스
Squarepoint Ops LLC Increases Stock Position in Disc Medicine, Inc. $IRON - MarketBeat
Disc Medicine (NASDAQ:IRON) Raised to "Hold" at Wall Street Zen - MarketBeat
Officer at Disc Medicine (NASDAQ: IRON) plans to sell 27,136 shares - Stock Titan
Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action InvestigationIRON - PR Newswire
Disc Medicine (NASDAQ:IRON) Shares Down 5%Should You Sell? - MarketBeat
The Technical Signals Behind (IRON) That Institutions Follow - Stock Traders Daily
Opaleye Management Inc. Raises Stock Position in Disc Medicine, Inc. $IRON - MarketBeat
Disc Medicine Shares Polycythemia Vera Data, Outlines Late 2026 Trial Milestones - Benzinga
IRON Reiterated by Wedbush -- Price Target Maintained at $100 - GuruFocus
Disc Medicine's Phase 2 rare blood cancer data; Frazier adds to public fund - Endpoints News
Form 8K Disc Medicine Inc For: 10 September By Investing.com - Investing.com South Africa
Disc Medicine reports promising DISC-3405 Phase 2 data - TipRanks
Disc Medicine's (IRON) "Outperform" Rating Reiterated at Wedbush - MarketBeat
Disc Medicine at Wells Fargo conference: two drug bets near key tests - Investing.com Canada
H.C. Wainwright reiterates Disc Medicine stock rating on trial data By Investing.com - Investing.com India
Disc Medicine reports Phase 2 DISC-3405 trial results - grafa.com
Jefferies reiterates Disc Medicine stock rating on polycythemia data By Investing.com - Investing.com Nigeria
Disc Medicine stock rating held at Outperform by BMO on trial data - Investing.com Canada
Disc Medicine reports positive phase 2 trial results for DISC-3405 By Investing.com - Investing.com South Africa
Disc Medicine (IRON) Reports Promising Phase 2 Data; Market Pric - GuruFocus
Disc Medicine reports positive phase 2 trial results for DISC-3405 - investing.com
Disc Medicine Reports Positive Initial RESTORE-PV Results for DISC-3405 in Polycythemia Vera - Quiver Quantitative
Blood-removal procedures fell from 4.0 at baseline to 0.6 after treatment - Stock Titan
Disc Medicine Investor News: If You Have Suffered Losses in - GlobeNewswire
Insider Selling: Disc Medicine (NASDAQ:IRON) Director Sells $135,052.44 in Stock - MarketBeat
Disc Medicine (NASDAQ: IRON) director sells shares under preset plan - Stock Titan
Disc Medicine at cantorfitzgerald healthcare conference: pipeline nears key tests - Investing.com Canada
Disc Medicine faces class action over alleged m... - Pluang
Legal & General Group Plc Invests $1.35 Million in Disc Medicine, Inc. $IRON - MarketBeat
Disc Medicine Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights - GlobeNewswire Inc.
Small Disc Medicine (NASDAQ: IRON) shareholder sale planned - Stock Titan
Disc Medicine (NASDAQ: IRON) files notice to sell about $60K in stock - Stock Titan
Disc Medicine (NASDAQ: IRON) holder plans $72K stock sale - Stock Titan
Proposed $176K Disc Medicine (NASDAQ: IRON) share sale by Atlas Venture Fund X - Stock Titan
Kevin Bitterman Sells 129 Shares of Disc Medicine (NASDAQ:IRON) Stock - MarketBeat
Insider Selling: Disc Medicine (NASDAQ:IRON) Director Sells $3,941,477.88 in Stock - MarketBeat
Kevin Bitterman Sells 5,203 Shares of Disc Medicine (NASDAQ:IRON) Stock - MarketBeat
Disc Medicine (IRON) director's funds sell 54K shares in 10b5-1 trades - Stock Titan
Disc Medicine(IRON.US) Director Sells US$4.37 Million in Common Stock - Moomoo
Atlas fund plans small Disc Medicine (NASDAQ: IRON) share sale - Stock Titan
Venture fund plans Disc Medicine (IRON) share sale - Stock Titan
Disc Medicine (NASDAQ: IRON) investor plans $225K stock sale - Stock Titan
Disc Medicine (IRON) investor plans 2,339-share sale - Stock Titan
Man Group plc Takes $1.09 Million Position in Disc Medicine, Inc. $IRON - MarketBeat
The Manufacturers Life Insurance Company Takes Position in Disc Medicine, Inc. $IRON - MarketBeat
Venture fund to sell 513 Disc Medicine (NASDAQ: IRON) shares - Stock Titan
Disc Medicine (NASDAQ: IRON) investor plans Rule 144 share sale - Stock Titan
Venture backer plans Disc Medicine (NASDAQ: IRON) share sale - Stock Titan
Venture fund plans Disc Medicine (IRON) share resale - Stock Titan
Disc Medicine Stock Slumps After FDA Declines Approval For Inherited Disorder Drug Over Efficacy Concerns - Stocktwits
IRON Maintained by Wedbush -- Price Target Raised to $100 - GuruFocus
Disc Medicine Inc (IRON) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Disc Medicine Inc 주식 (IRON) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Bitterman Kevin | Director |
Sep 11 '26 |
Option Exercise |
45.07 |
27,136 |
1,223,144 |
27,136 |
| Bitterman Kevin | Director |
Sep 11 '26 |
Sale |
70.11 |
27,136 |
1,902,505 |
0 |
0.88%
자본화:
|
볼륨(24시간):